540 related articles for article (PubMed ID: 27238177)
1. Fungal infection of cystic fibrosis patients - single center experience.
Garczewska B; Jarzynka S; Kuś J; Skorupa W; Augustynowicz-Kopeć E
Pneumonol Alergol Pol; 2016; 84(3):151-9. PubMed ID: 27238177
[TBL] [Abstract][Full Text] [Related]
2. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole.
Burgel PR; Baixench MT; Amsellem M; Audureau E; Chapron J; Kanaan R; Honoré I; Dupouy-Camet J; Dusser D; Klaassen CH; Meis JF; Hubert D; Paugam A
Antimicrob Agents Chemother; 2012 Feb; 56(2):869-74. PubMed ID: 22123701
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
Johnson EM; Szekely A; Warnock DW
J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
[TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibility patterns for Aspergillus, Scedosporium, and Exophiala isolates recovered from cystic fibrosis patients against amphotericin B, and three triazoles and their impact after long-term therapies.
Brito Devoto T; Hermida-Alva K; Posse G; Finquelievich JL; García-Effrón G; Cuestas ML
Med Mycol; 2023 Aug; 61(8):. PubMed ID: 37591630
[TBL] [Abstract][Full Text] [Related]
8. [Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital].
Skrodeniene E; Dambrauskiene A; Vitkauskiene A
Medicina (Kaunas); 2006; 42(4):294-9. PubMed ID: 16687901
[TBL] [Abstract][Full Text] [Related]
9. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.
Özmerdiven GE; Ak S; Ener B; Ağca H; Cilo BD; Tunca B; Akalın H
J Infect Chemother; 2015 Aug; 21(8):581-6. PubMed ID: 26048062
[TBL] [Abstract][Full Text] [Related]
10. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
11. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
12. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
Pfaller MA; Carvalhaes CG; Messer SA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115473. PubMed ID: 34352433
[TBL] [Abstract][Full Text] [Related]
14. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
Espinel-Ingroff A; Johnson E; Hockey H; Troke P
J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
16. Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?
Hamprecht A; Morio F; Bader O; Le Pape P; Steinmann J; Dannaoui E
Mycopathologia; 2018 Feb; 183(1):151-160. PubMed ID: 28653258
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis.
Morio F; Aubin GG; Danner-Boucher I; Haloun A; Sacchetto E; Garcia-Hermoso D; Bretagne S; Miegeville M; Le Pape P
J Antimicrob Chemother; 2012 Aug; 67(8):1870-3. PubMed ID: 22581906
[TBL] [Abstract][Full Text] [Related]
18. Scedosporium apiospermum complex in cystic fibrosis; should we treat?
Noni M; Katelari A; Kapi A; Stathi A; Dimopoulos G; Doudounakis SE
Mycoses; 2017 Sep; 60(9):594-599. PubMed ID: 28504471
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the conjunctival fungal flora and its susceptibility to antifungal agents in healthy horses in Switzerland.
Voelter-Ratson K; Monod M; Unger L; Spiess BM; Pot SA
Vet Ophthalmol; 2014 Jul; 17 Suppl 1():31-6. PubMed ID: 23910390
[TBL] [Abstract][Full Text] [Related]
20. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
Manavathu EK; Abraham OC; Chandrasekar PH
Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
